# Boston Scientific Corporation: Observational study closed enrollment, 550 enrolled (Atrial Fibrillation, Pulsed Field Ablation)

**Score:** 85/100

| Field | Value |
|---|---|
| Sponsor | Boston Scientific Corporation |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Registry on the FARAVIEW Technology of the OPAL HDx Mapping System When Used With the FARAWAVE NAV Ablation Catheter in the Treatment of Atrial Fibrillation |
| NCT ID | NCT06808217 |
| Phase | Observational |
| Status | active not recruiting |
| Conditions | Atrial Fibrillation; Pulsed Field Ablation; FARAPULSE |
| Intervention types | device |
| Target enrollment | 550 |
| Site countries | Austria, France, Germany, Greece, Ireland, Italy, Monaco, Netherlands, Spain, Switzerland |
| Posted | 2025-02-05 |
| Planned start | 2025-07-30 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-23 |
| Last update posted | 2026-10-23 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- 550 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06808217). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.